Compare Stocks: SGMO, HURA, KZIA, and FHTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FHTX Foghorn Therapeutics	$2.00 +0.5%	$4.82	$1.79 ▼ $7.61	$118.18M	3.01	1.34 million shs	646,749 shs
HURA TuHURA Biosciences	$1.96 +1.6%	$2.10	$0.41 ▼ $3.43	$122.99M	-0.21	216,857 shs	148,973 shs
KZIA Novogen	$8.93 +1.2%	$11.80	$4.86 ▼ $17.40	$114.39M	2.26	273,956 shs	123,435 shs
SGMO Sangamo Therapeutics	$0.07	$0.07	$0.06 ▼ $0.77	$30.66M	1.3	8.10 million shs	N/A

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FHTX Foghorn Therapeutics	+0.50%	-0.99%	-57.17%	-66.39%	-55.56%
HURA TuHURA Biosciences	+1.55%	+2.62%	-2.49%	-17.99%	-24.90%
KZIA Novogen	+1.25%	-3.67%	-24.83%	-34.14%	+24.72%
SGMO Sangamo Therapeutics	0.00%	0.00%	0.00%	0.00%	-89.30%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FHTX Foghorn Therapeutics	$2.00 +0.5%	$4.82	$1.79 ▼ $7.61	$118.18M	3.01	1.34 million shs	646,749 shs
HURA TuHURA Biosciences	$1.96 +1.6%	$2.10	$0.41 ▼ $3.43	$122.99M	-0.21	216,857 shs	148,973 shs
KZIA Novogen	$8.93 +1.2%	$11.80	$4.86 ▼ $17.40	$114.39M	2.26	273,956 shs	123,435 shs
SGMO Sangamo Therapeutics	$0.07	$0.07	$0.06 ▼ $0.77	$30.66M	1.3	8.10 million shs	N/A

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FHTX Foghorn Therapeutics	+0.50%	-0.99%	-57.17%	-66.39%	-55.56%
HURA TuHURA Biosciences	+1.55%	+2.62%	-2.49%	-17.99%	-24.90%
KZIA Novogen	+1.25%	-3.67%	-24.83%	-34.14%	+24.72%
SGMO Sangamo Therapeutics	0.00%	0.00%	0.00%	0.00%	-89.30%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FHTX Foghorn Therapeutics	2.30	Hold	$6.67	233.33% Upside
HURA TuHURA Biosciences	2.67	Moderate Buy	$9.00	359.18% Upside
KZIA Novogen	2.67	Moderate Buy	$28.80	222.51% Upside
SGMO Sangamo Therapeutics	1.75	Reduce	$5.50	7,332.43% Upside

Current Analyst Ratings Breakdown

Latest SGMO, HURA, KZIA, and FHTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/2/2026	FHTX Foghorn Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$12.00 ➝ $5.00
10/2/2026	FHTX Foghorn Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$10.00 ➝ $2.00
10/2/2026	FHTX Foghorn Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$12.00 ➝ $5.00
10/2/2026	FHTX Foghorn Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$13.00 ➝ $5.00
10/1/2026	FHTX Foghorn Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold
10/1/2026	FHTX Foghorn Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
10/1/2026	FHTX Foghorn Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Market Outperform ➝ Market Perform
10/1/2026	FHTX Foghorn Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$5.00
10/1/2026	FHTX Foghorn Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
9/17/2026	FHTX Foghorn Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
9/10/2026	KZIA Novogen	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$40.00

(Data available from 10/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FHTX Foghorn Therapeutics	$30.91M	3.84	N/A	N/A	($1.92) per share	-1.04
HURA TuHURA Biosciences	N/A	N/A	N/A	N/A	$0.34 per share	N/A
KZIA Novogen	$1.23M	94.16	N/A	N/A	($5.34) per share	-1.67
SGMO Sangamo Therapeutics	$39.55M	0.78	N/A	N/A	($0.04) per share	-1.85

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FHTX Foghorn Therapeutics	-$74.28M	-$0.98	N/A	N/A	N/A	-175.78%	N/A	-31.17%	11/4/2026 (Estimated)
HURA TuHURA Biosciences	-$30.05M	-$0.54	N/A	N/A	N/A	N/A	-156.47%	-106.98%	11/13/2026 (Estimated)
KZIA Novogen	-$13.41M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SGMO Sangamo Therapeutics	-$122.93M	-$0.38	N/A	N/A	N/A	-310.81%	-2,662.06%	-132.12%	N/A

Latest SGMO, HURA, KZIA, and FHTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/4/2026	Q3 2026	FHTX Foghorn Therapeutics	-$0.23	N/A	N/A	N/A	$6.39 million	N/A
8/14/2026	Q2 2026	HURA TuHURA Biosciences	-$0.1533	-$0.14	+$0.0133	-$0.14	N/A	N/A
8/6/2026	Q2 2026	FHTX Foghorn Therapeutics	-$0.2450	-$0.10	+$0.1450	-$0.10	$6.81 million	$16.07 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
FHTX Foghorn Therapeutics	N/A	N/A	N/A	N/A	N/A
HURA TuHURA Biosciences	N/A	N/A	N/A	N/A	N/A
KZIA Novogen	N/A	N/A	N/A	N/A	N/A
SGMO Sangamo Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FHTX Foghorn Therapeutics	N/A	3.36	3.36
HURA TuHURA Biosciences	0.20	0.18	0.18
KZIA Novogen	N/A	N/A	N/A
SGMO Sangamo Therapeutics	N/A	0.84	0.84

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FHTX Foghorn Therapeutics	61.55%
HURA TuHURA Biosciences	0.62%
KZIA Novogen	30.89%
SGMO Sangamo Therapeutics	56.92%

Insider Ownership

Company	Insider Ownership
FHTX Foghorn Therapeutics	9.02%
HURA TuHURA Biosciences	6.06%
KZIA Novogen	1.00%
SGMO Sangamo Therapeutics	4.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FHTX Foghorn Therapeutics	106	59.38 million	54.03 million	Optionable
HURA TuHURA Biosciences	22	63.73 million	59.87 million	N/A
KZIA Novogen	6	12.97 million	12.84 million	No Data
SGMO Sangamo Therapeutics	480	414.29 million	397.29 million	Optionable

SGMO, HURA, KZIA, and FHTX Headlines

Recent News About These Companies

Sangamo Therapeutics Completes Fabry Gene Therapy Asset Sale

September 21, 2026 | tipranks.com

Sangamo Therapeutics stock falls after Nasdaq delisting to OTC market

September 19, 2026 | ad-hoc-news.deA

Sangamo Therapeutics Advances Bankruptcy Asset Sale Process

July 20, 2026 | tipranks.com

Sangamo Therapeutics Inc SGMO

July 7, 2026 | morningstar.comM

Sangamo Therapeutics Enters Into Asset Sale Agreements with Lilly and Astellas

June 24, 2026 | markets.businessinsider.com

Sangamo falls after Chapter 11 bankruptcy filing; Eli Lilly and Astellas to acquire key assets

June 24, 2026 | seekingalpha.com

Sangamo Therapeutics files for Chapter 11 bankruptcy

June 24, 2026 | msn.com

Sangamo Therapeutics Initiates Chapter 11 and Asset Sales

June 23, 2026 | tipranks.com

Sangamo Therapeutics Announces Exploration of Strategic Alternatives to Maximize Value for Stakeholders

June 8, 2026 | globenewswire.com

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q1 2026 Earnings Call Transcript

May 16, 2026 | insidermonkey.com

Sangamo Therapeutics Inc (SGMO) Q1 2026 Earnings Call Highlights: Progress Amidst Financial ...

May 16, 2026 | finance.yahoo.com

Sangamo Therapeutics Reports No Unregistered Equity Sales or Share Repurchases for the Period

May 16, 2026 | tipranks.com

Sangamo Therapeutics, Inc. (SGMO) Q1 2026 Earnings Call Transcript

May 14, 2026 | seekingalpha.com

Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates

May 14, 2026 | zacks.com

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2026 Financial Results

May 14, 2026 | globenewswire.com

Sangamo Therapeutics Announces First Quarter 2026 Earnings Call

May 11, 2026 | markets.businessinsider.com

Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Transition to Trading on OTCQB Venture Market

May 5, 2026 | finanznachrichten.de

Sangamo Therapeutics to Present Pipeline and Technology Advances at the 29th Annual Meeting of The American Society of Gene & Cell Therapy (ASGCT)

April 30, 2026 | globenewswire.com

Sangamo Therapeutics (SGMO) Nasdaq delisting shifts stock to OTCQB market

April 29, 2026 | finance.yahoo.com

Sangamo Therapeutics Announces Transition to Trading on OTCQB Venture Market

April 29, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGMO, HURA, KZIA, and FHTX Company Descriptions

Foghorn Therapeutics NASDAQ:FHTX

$2.00 +0.01 (+0.50%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$2.00 0.00 (0.00%)

As of 10/9/2026 07:30 PM Eastern

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

TuHURA Biosciences NASDAQ:HURA

$1.96 +0.03 (+1.55%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$1.98 +0.02 (+1.02%)

As of 10/9/2026 07:30 PM Eastern

TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.

Novogen NASDAQ:KZIA

$8.93 +0.11 (+1.25%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$8.90 -0.04 (-0.39%)

As of 10/9/2026 07:30 PM Eastern

Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company's lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Sangamo Therapeutics NASDAQ:SGMO

$0.07 0.00 (0.00%)

As of 10/8/2026

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SGMO, HURA, KZIA, and FHTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SGMO, HURA, KZIA, and FHTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SGMO, HURA, KZIA, and FHTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGMO, HURA, KZIA, and FHTX Company Descriptions

Foghorn Therapeutics NASDAQ:FHTX

TuHURA Biosciences NASDAQ:HURA

Novogen NASDAQ:KZIA

Sangamo Therapeutics NASDAQ:SGMO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SGMO, HURA, KZIA, and FHTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SGMO, HURA, KZIA, and FHTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SGMO, HURA, KZIA, and FHTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGMO, HURA, KZIA, and FHTX Company Descriptions

Foghorn Therapeutics NASDAQ:FHTX

TuHURA Biosciences NASDAQ:HURA

Novogen NASDAQ:KZIA

Sangamo Therapeutics NASDAQ:SGMO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools